Kala Pharma reveals mixed Ph3 data for dry eye disease drug

This article was originally published here

Kala Pharmaceuticals (NSDQ:KALA) shares dropped -28% today after the company revealed mixed results from two Phase III trials of its dry eye disease drug, KPI-121.

In its Stride 1 trial, the company’s drug met statistical significance for the primary endpoint of conjuctival hyperemia change from baseline to day 15, as well as the primary endpoint of ocular discomfort severity change from baseline to day 15. However, the product did not meet its inferior corneal staining change endpoint.

Get the full story at our sister site, Drug Delivery Business News.

The post Kala Pharma reveals mixed Ph3 data for dry eye disease drug appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply